Key facts
- It has raised $5.8M; the latest was Seed Round ($5.2M) in Feb 2025.
- Notable investors include Denmark's Export and Investment Fund, Nordic Mentor Network For Entrepreneurship, BioInnovation Institute, HCVC, Merck.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Fuse Vectors
- ·The full record, as it builds
Funding rounds
No funding rounds for Fuse Vectors are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fuse Vectors
Developer of a biotech platform designed to transform gene therapy production through innovative cell-free technology. The company offers faster, scalable, and high-quality production of viral vectors, enabling pharmaceutical companies, biotech firms, and academic institutions to make gene therapies safer, more efficient, and accessible to patients worldwide.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2022
- Employees
- 10
- Website
- fusevectors.com/
- Ownership
- Privately Held (backing)
Fuse Vectors doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fuse Vectors shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fuse Vectors in its N-PORT filings yet. We sweep new filings monthly.